Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) FCF Margin (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed FCF Margin for 14 consecutive years, with 576.44% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin rose 71000.0% year-over-year to 576.44%; the TTM value through Mar 2026 reached 576.24%, up 51439.0%, while the annual FY2025 figure was 690.86%, 38187.0% up from the prior year.
  • FCF Margin hit 576.44% in Q1 2026 for Agios Pharmaceuticals, down from 481.59% in the prior quarter.
  • Across five years, FCF Margin topped out at 481.59% in Q4 2025 and bottomed at 11931.61% in Q1 2022.
  • Average FCF Margin over 5 years is 1729.43%, with a median of 1023.82% recorded in 2023.
  • Year-over-year, FCF Margin skyrocketed 1022753bps in 2023 and then tumbled -23239bps in 2024.
  • Agios Pharmaceuticals' FCF Margin stood at 1537.73% in 2022, then skyrocketed by 33bps to 1023.82% in 2023, then fell by -23bps to 1256.21% in 2024, then surged by 62bps to 481.59% in 2025, then fell by -20bps to 576.44% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 576.44%, 481.59%, and 674.27% for Q1 2026, Q4 2025, and Q3 2025 respectively.